A man in his 80’s presented to our hospital's emergency department with left hip pain
after falling while transferring from a wheelchair on a visit day. He had been taking
clopidogrel for > 10 years after atherothrombotic stroke and apixaban 2.5 mg b.i.d.
for 2 years since he was diagnosed with deep vein thrombosis. The patient had no coagulation
abnormalities when he started apixaban therapy and had never experienced bleeding
events. His medical history included cervical spondylosis surgery, right femoral neck
fracture, hypertension, and benign prostatic hypertrophy. Other medications included
candesartan, amlodipine, enalapril, tamsulosin, and tadalafil. He denied any overdose
of prescribed medications. The patient had no family history of bleeding disorders.
He was a non-smoker and did not drink alcohol.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Rinsho Byori. 2009; 57 (Japanese): 999-1003
- Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.J Thromb Haemost. 2018; 16: 209-219https://doi.org/10.1111/jth.13912
- Acquired haemophilia: an often overlooked cause of bleeding - experience from a Hungarian tertiary care centre.Blood Coagul Fibrinolysis. 2012; 23: 584-589https://doi.org/10.1097/MBC.0b013e3283551102
- Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation.Dtsch Arztebl Int. 2014; 111: 345-348https://doi.org/10.3238/arztebl.2014.0345
- Acquired hemophilia A in an elderly patient on apixaban therapy.Isr Med Assoc J. 2021; 23: 130-131
- "Accessory after the factors": A rare case of an acquired factor VIII inhibitor in a 75-year-old man on rivaroxaban.Cureus. 2021; 13: e18597https://doi.org/10.7759/cureus.18597
- Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.J Arrhythm. 2016; 32: 42-50https://doi.org/10.1016/j.joa.2015.08.001
- A study on indices of apixaban anticoagulation: A single-center prospective study.J Pharmacol Sci. 2018; 137: 105-109https://doi.org/10.1016/j.jphs.2018.05.001
- Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.Thromb Res. 2015; 136: 148-153https://doi.org/10.1016/j.thromres.2015.04.030
Article info
Publication history
Accepted:
January 23,
2023
Received:
January 6,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Funding source: None
Conflict of interest statement: All authors declare no conflict of interest.
All authors had access to the data. MK wrote the initial draft, and YH, AH, and ST revised the manuscript.
Identification
Copyright
© 2023 Published by Elsevier Inc.
